A randomized clinical trial study on the efficacy and safety of adalimumab and methylprednisolone pulse therapy in the treatment of COVID-19 patients with acute respiratory distress syndrome

Introduction: Adalimumab reduces the expression of angiotensin-converting enzyme (ACE2) receptor at cell surface, therefore it is thought to be effective in treating patients with COVID-19. Objectives: The present study was conducted evaluate effectiveness adalimumab and pulsed corticosteroids severe acute respiratory failure due Patients Methods: double-blind clinical trial carried out on COVID-19 referred Imam Reza hospital, Tehran. were randomly divided into two groups intervention (patients under standard treatment according national protocol Iran + methylprednisolone adalimumab) control methylprednisolone). Results: patients’ hospitalization information shows that duration group significantly shorter than their counterparts (P=0.041). Serum levels total bilirubin ninth day (P=0.043) GCS (Glasgow coma scale) (P=0.041) tenth (P=0.039) increased compared group. However, direct value eighth (P=0.031), serum creatinine 8th (P=0.047), 9th (P=0.047) 10th days also PEEF (pericarditis/pericardial effusion) lower Conclusion: administration increases length hospital stay. Trial Registration: This designed as a (identifier: IRCT20200406046963N2, https://www.irct.ir/trial/55011), has been approved by ethics committee biomedical research AJA University Medical Sciences (#IR.AJAUMS.REC.1400.032).